FDA
-
-
-
-
-
-
-
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMIĀ® Label Expansion in the At-Home Setting
-
-
-
-
-
-
-
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
-
-
-
-
-
-
-
BioXcel announces positive results from IGALMI at-home trial
-
-
-
-
-
-
-
BioXcel completes database lock for BXCL501 agitation trial
-
-
-
-
-
-
-
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
-
-
-
-
-
-
-
BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMIĀ®
-
-
-
-
-
-
-
WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

